RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone using the numbers (800) 715-9871 or (646) 307-1963 with conference code 633359, or listen to the webcast through the company's investor relations website.
RxSight (NASDAQ:RXST), azienda di dispositivi medici oftalmici specializzata in soluzioni personalizzate per la visione post-intervento di cataratta, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 7 agosto 2025, dopo la chiusura dei mercati.
La società terrà una conference call alle 13:30 PT / 16:30 ET per discutere i risultati. Gli investitori potranno partecipare telefonicamente chiamando i numeri (800) 715-9871 o (646) 307-1963 con il codice di conferenza 633359, oppure ascoltare la diretta streaming tramite il sito web delle relazioni con gli investitori della società.
RxSight (NASDAQ:RXST), una empresa de dispositivos médicos oftálmicos enfocada en soluciones de visión personalizadas para pacientes post-cirugía de cataratas, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 7 de agosto de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia a las 1:30 PM PT / 4:30 PM ET para discutir los resultados. Los inversores pueden unirse por teléfono llamando a los números (800) 715-9871 o (646) 307-1963 con el código de conferencia 633359, o escuchar la transmisión en vivo a través del sitio web de relaciones con inversionistas de la empresa.
RxSight (NASDAQ:RXST)는 백내장 수술 후 맞춤형 시력 솔루션에 중점을 둔 안과 의료기기 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 7일 장 마감 후로 예정했습니다.
회사는 오후 1:30 PT / 오후 4:30 ET에 실적 관련 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 (800) 715-9871 또는 (646) 307-1963번으로 회의 코드 633359를 입력해 전화로 참여할 수 있으며, 회사 투자자 관계 웹사이트를 통해 웹캐스트도 청취할 수 있습니다.
RxSight (NASDAQ:RXST), une entreprise de dispositifs médicaux ophtalmiques spécialisée dans les solutions de vision personnalisées pour les patients après une chirurgie de la cataracte, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 7 août 2025, après la clôture du marché.
La société tiendra une conférence téléphonique à 13h30 PT / 16h30 ET pour discuter des résultats. Les investisseurs peuvent participer par téléphone en appelant les numéros (800) 715-9871 ou (646) 307-1963 avec le code de conférence 633359, ou écouter la diffusion en direct via le site web des relations investisseurs de l'entreprise.
RxSight (NASDAQ:RXST), ein Unternehmen für ophthalmologische Medizinprodukte, das sich auf maßgeschneiderte Sehlösungen für Patienten nach Kataraktoperationen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das 2. Quartal 2025 für den 7. August 2025 nach Börsenschluss terminiert.
Das Unternehmen wird um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können telefonisch über die Nummern (800) 715-9871 oder (646) 307-1963 mit dem Konferenzcode 633359 teilnehmen oder den Webcast über die Investor-Relations-Website des Unternehmens verfolgen.
- None.
- None.
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
FAQ
When will RxSight (RXST) report Q2 2025 earnings?
What time is RxSight's Q2 2025 earnings call?
How can I listen to RxSight's Q2 2025 earnings call?
What does RxSight (RXST) company do?
